Life sciences
Subscribe to Life sciences's Posts

McDermott Partners Recognized As Digital Health Power Players

Washington (August 11, 2021) – McDermott Will & Emery partners Jennifer Geetter and Vernessa Pollard have been recognized within an Insider profile on the “9 behind-the-scenes players who can make or break your digital-health startup.” The pair discussed advising young companies on the regulatory hurdles they have to clear before tackling the healthcare market.

As part of the Firm’s industry-leading health practice, Jennifer advises digital health companies on the development, delivery and implementation of innovative healthcare solutions. Vernessa leads medical device and technology companies through US Food and Drug Administration (FDA) regulations to bring products to market.

Vernessa explored with Insider how more tech companies are spreading into healthcare. These companies need assistance discussing the FDA’s newest regulations, including machine learning oversights or health-data privacy rules. If businesses are not knowledgeable about their regulatory requirements, it can make or break their investments.

“We have a number of what we’d consider to be nontraditionally FDA regulated entities, such as the large tech companies and even hospitals and healthcare providers, that are entering this space because they’re developing new tools or technology that may trigger FDA requirements,” Vernessa noted.

Jennifer explained that it’s not always clear if decade old FDA laws apply, so she advises her clients to prioritize building trust with patients through an emphasis of privacy and cybersecurity protection.

“There’s something about the intimacy of the standard doctor-patient relationship when you’re sitting across the room from your doctor that breeds trust,” Jennifer said. “When you’re in a digital healthcare system with distance, you don’t necessarily have that.”

McDermott Will & Emery is the nation’s leading health law firm. The Health Industry Advisory group is the only health practice to receive top national rankings from U.S. News – Best Lawyers “Best Law Firms,” Chambers USA, The Legal 500 US and Law360. The practice was also recognized by Chambers as “Health Team of the Year” in 2010, 2013, 2017 and 2019. McDermott has also held the top spot in PitchBook’s League Tables as the most active firm for healthcare private equity since 2017.

FDA’s Breakthrough Device Program: Opportunities and Challenges for Device Developers

As part of the 21st Century Cures Act, Congress gave the US Food and Drug Administration (FDA) the authority to establish a Breakthrough Devices Program intended to expedite the development and prioritize the review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating disease or conditions. In December 2018, FDA issued a guidance document describing policies FDA intends to use to implement the Program.

There are two criteria for inclusion in the Breakthrough Device Program:

  1. The device must provide for a more effective treatment or diagnosis of a life-threatening or irreversibly debilitating human disease or condition; and
  2. The device must (i) represent breakthrough technology, (ii) have no approved or cleared alternatives, (iii) offer significant advantages over existing approved or cleared alternatives, or (iv) demonstrate that its availability is in the best interest of patients.


UPCOMING WEBINAR | Digital Health: The New Dynamics — Big Data Part I: Data-Driven Life Sciences Innovation, Personalized Medicine and Research

Health care and life sciences companies increasingly operate in a digital environment. McDermott Will & Emery is hosting a complimentary four-part webinar series to explore the practical business considerations and to simplify the regulatory complexity of digital health, including health information technology (IT), big data, mobile health and telehealth.


Big Data Part I: Data-Driven Life Sciences Innovation, Personalized Medicine and Research

Date:  Tuesday, December 9
Time: 12:00 – 1:30 pm EST

Data-driven solutions are a powerful tool for the life sciences sector and research community. This program will explore how life sciences companies, research institutions, providers and informatics businesses can successfully navigate the regulatory landscape for big data to develop, introduce and differentiate products. The following key questions, among others, will be addressed:

  • Overview of Regulatory Framework — How can big data initiatives be structured to comply with key federal laws?
  • Data Registry Creation and Management — What are the data stewardship and data governance considerations?
  • Emerging Partnerships — What is the role of the government and industry for data initiatives in the life sciences?
  • Personalized Medicine — How is data used to deliver personalized medicine at the bedside?
  • Biospecimens — How does the introduction of annotated biospecimens affect the big data landscape?
  • Genomic Age – What does it mean to engage in big data initiatives in an age of genomic medicine?


Amy Hooper Kearbey, Partner, McDermott Will & Emery LLP

Matthew Hawryluk, Ph.D., Senior Director, Corporate & Business Development, Foundation Medicine, Inc.

Jennifer C. King, Ph.D., Director of Data Governance for CancerLinQ, American Society of Clinical Oncologists

Sari Heller Ratican, Chief Privacy Officer, Amgen


Jennifer S. Geetter, Partner, McDermott Will & Emery LLP


  • WEBINAR THREE: Big Data Part 2: Data-Driven Changes to Payment Models, January 13, 2015
  • WEBINAR FOUR: Mobile Health & Telehealth: Mobile and Telehealth Technology Create New Business Opportunities, February 10, 2015

Click here to view WEBINAR ONE: Health IT: Collection, analysis and sharing of health information

For more information, please contact McDermott Events.




2021 Chambers USA top ranked firm
LEgal 500 EMEA top tier firm 2021
U.S. News Law Firm of the Year 2022 Health Care Law